Immunotherapy for repeat nasopharyngeal cancer after it returns
Treatments studied
Part of Cancer, Ear, nose & throat, Mouth & dental clinical trials.
This trial studies toripalimab (an immunotherapy that helps your immune system attack cancer) for nasopharyngeal cancer that has come back locally. It may help shrink or control the returning tumor and improve outcomes for people who meet the safety and lab requirements.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Your nasopharyngeal cancer has returned (confirmed by biopsy or scans).
- Your scan stage must match rT3–4 with N0–1 or rT1–4 with N2–3, and no distant spread (M0).
- You’re age 18 to 65, and you have good daily functioning (ECOG 0–1).
- Your blood counts and organs must be strong enough (white blood cells, platelets, hemoglobin, plus liver and kidney tests).
- You do not have active hepatitis B with high virus levels, hepatitis C, HIV, or other major uncontrolled infections.
- You can safely take immunotherapy (no major autoimmune disease, no prior interstitial lung disease, and no recent steroids/immunosuppressants or live vaccines).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at whether adding chemo-immunotherapy after surgery is better than surgery alone for patients whose nasopharyngeal cancer has returned but is still in early stages. It may help prevent the cancer from coming back again.
This trial compares giving chemotherapy and immunotherapy before surgery (neoadjuvant) versus after surgery (adjuvant) for patients whose nasopharyngeal cancer has returned locally. It aims to find which approach works better to control the cancer.
This trial compares two treatments for early-stage nasopharyngeal cancer that has returned after radiation: surgery versus intensity-modulated radiation therapy (IMRT). The goal is to see which approach is more effective at controlling the cancer while keeping side effects manageable.
This phase 3 trial tests whether adding toripalimab (an immunotherapy medicine) to standard chemo-radiation works better for treating nasopharyngeal cancer that has come back and cannot be removed by surgery. It aims to improve control of the cancer after it returns.
This trial studies whether adding an anti–PD-1 immunotherapy to standard chemoradiotherapy can control nasopharyngeal cancer that has come back in the local area. It may help patients live longer or have the cancer respond better compared with chemoradiotherapy alone.
This trial tests whether adding an immunotherapy drug (which helps your immune system fight cancer) to standard chemotherapy can improve outcomes for people with advanced nasopharyngeal cancer (a type of cancer in the upper throat). If you qualify, you would receive this combination treatment as your first therapy for this stage of disease.
Hear when a new Recurrent Nasopharyngeal Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.